degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostata-neoplasmen - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
arelix mite 3 mg tabletten
sanofi-aventis deutschland gmbh (8030868) - piretanid - tablette - teil 1 - tablette; piretanid (21612) 3 milligramm
arelix 6 mg tabletten
sanofi-aventis deutschland gmbh (8030868) - piretanid - tablette - teil 1 - tablette; piretanid (21612) 6 milligramm
arelix rr 6 mg retardkapseln
sanofi-aventis deutschland gmbh (8030868) - piretanid - hartkapsel, retardiert - teil 1 - hartkapsel, retardiert; piretanid (21612) 6 milligramm
arelix ace
sanofi-aventis deutschland gmbh (8030868) - piretanid; ramipril - tablette - teil 1 - tablette; piretanid (21612) 6 milligramm; ramipril (22686) 5 milligramm
betarelix mite 20/3mg
puren pharma gmbh & co. kg (8034441) - penbutololsulfat (ph.eur.); piretanid - filmtablette - teil 1 - filmtablette; penbutololsulfat (ph.eur.) (18040) 20 milligramm; piretanid (21612) 3 milligramm
firmagon
ferring pharmaceuticals a/s - degarelix - prostata-neoplasmen - endokrine therapie - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
betarelix 40/6mg
puren pharma gmbh & co. kg (8034441) - penbutololsulfat (ph.eur.); piretanid - filmtablette - teil 1 - filmtablette; penbutololsulfat (ph.eur.) (18040) 40 milligramm; piretanid (21612) 6 milligramm
firmagon 80 mg pulver und lösungsmittel zur herstellung einer injektionssuspension (lösungsmittel in fertigspritze)
ferring ag - degarelixum - pulver und lösungsmittel zur herstellung einer injektionssuspension (lösungsmittel in fertigspritze) - praeparatio cryodesiccata: degarelixum 80 mg ut degarelixi acetas 88.2 mg, mannitolum, pro vitro. solvens: aqua ad iniectabile 4.2 ml. - gnrh-rezeptorenblocker zur behandlung von prostatakarzinom - synthetika
firmagon 120 mg pulver und lösungsmittel zur herstellung einer injektionssuspension (lösungsmittel in fertigspritze)
ferring ag - degarelixum - pulver und lösungsmittel zur herstellung einer injektionssuspension (lösungsmittel in fertigspritze) - praeparatio cryodesiccata: degarelixum 120 mg ut degarelixi acetas 128 mg, mannitolum, pro vitro. solvens: aqua ad iniectabile 3 ml. - gnrh-rezeptorenblocker zur behandlung von prostatakarzinom - synthetika